Predictors of teriparatide treatment failure in patients with low bone mass

INTRODUCTION: While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass. METHOD: We performed a retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Elraiyah, Tarig, Ahmed, Adil H., Wang, Zhen, Farr, Joshua N., Murad, Mohammad H., Drake, Matthew T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926837/
https://www.ncbi.nlm.nih.gov/pubmed/28326338
http://dx.doi.org/10.1016/j.bonr.2015.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926837/
https://www.ncbi.nlm.nih.gov/pubmed/28326338
http://dx.doi.org/10.1016/j.bonr.2015.11.001

Ejemplares similares